OncoZenge AB (publ) (ONCOZ.ST)
SEK 5.09
(-0.39%)
SEK 5.09
(-0.39%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.69 Million SEK | -41.82% |
| 2022 | 2.92 Million SEK | -40.46% |
| 2021 | 4.9 Million SEK | -45.6% |
| 2020 | 9.01 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 967 Thousand SEK | -43.08% |
| 2024 Q2 | 724 Thousand SEK | -25.13% |
| 2023 Q1 | 1.68 Million SEK | -42.29% |
| 2023 Q4 | 1.69 Million SEK | -37.21% |
| 2023 Q2 | 2.39 Million SEK | 42.02% |
| 2023 FY | 1.69 Million SEK | -41.82% |
| 2023 Q3 | 2.7 Million SEK | 13.08% |
| 2022 FY | 2.92 Million SEK | -40.46% |
| 2022 Q2 | -1.01 Million SEK | -122.63% |
| 2022 Q4 | 2.92 Million SEK | 48.3% |
| 2022 Q1 | 4.5 Million SEK | -8.2% |
| 2022 Q3 | 1.96 Million SEK | 293.23% |
| 2021 Q2 | 1.38 Million SEK | -89.23% |
| 2021 FY | 4.9 Million SEK | -45.6% |
| 2021 Q4 | 4.9 Million SEK | 98.7% |
| 2021 Q3 | 2.46 Million SEK | 78.45% |
| 2021 Q1 | 12.84 Million SEK | 0.0% |
| 2020 FY | 9.01 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alzinova AB (publ) | 9.33 Million SEK | 81.792% |
| Amniotics AB (publ) | 10.54 Million SEK | 83.891% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | 61.613% |
| BioArctic AB (publ) | 139.5 Million SEK | 98.782% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 99.891% |
| Genovis AB (publ.) | 98.04 Million SEK | 98.267% |
| LIDDS AB (publ) | 3.75 Million SEK | 54.766% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 98.63% |
| Saniona AB (publ) | 86.08 Million SEK | 98.026% |
| Simris Alg AB (publ) | 148.93 Million SEK | 98.859% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 95.842% |
| AcouSort AB (publ) | 10.37 Million SEK | 83.629% |
| Active Biotech AB (publ) | 13.4 Million SEK | 87.321% |
| Camurus AB (publ) | 414.81 Million SEK | 99.59% |
| Cantargia AB (publ) | 54.97 Million SEK | 96.909% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | 55.732% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | 90.813% |
| Mendus AB (publ) | 51.22 Million SEK | 96.683% |
| Kancera AB (publ) | 17.97 Million SEK | 90.55% |
| Karolinska Development AB (publ) | 11.56 Million SEK | 85.314% |
| Lipum AB (publ) | 7.53 Million SEK | 77.461% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | 67.061% |
| NextCell Pharma AB | 13.68 Million SEK | 87.589% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 99.648% |
| Xintela AB (publ) | 14.01 Million SEK | 87.877% |
| Ziccum AB (publ) | 6.38 Million SEK | 73.403% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | 87.663% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | 27.978% |
| Isofol Medical AB (publ) | 19.16 Million SEK | 91.134% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 97.635% |
| CombiGene AB (publ) | 4.15 Million SEK | 59.119% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 97.611% |
| Intervacc AB (publ) | 21.68 Million SEK | 92.163% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 98.406% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 95.09% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 93.639% |
| Corline Biomedical AB | 6.78 Million SEK | 74.974% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 97.231% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | 89.458% |
| Aptahem AB (publ) | 8.99 Million SEK | 81.118% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 96.321% |
| Fluicell AB (publ) | 8.91 Million SEK | 80.942% |
| Biovica International AB (publ) | 34.76 Million SEK | 95.113% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | 85.439% |
| Abliva AB (publ) | 16.78 Million SEK | 89.875% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 99.208% |
| 2cureX AB (publ) | 2.93 Million SEK | 42.112% |
| I-Tech AB | 16.2 Million SEK | 89.516% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 99.857% |
| Cyxone AB (publ) | 4.69 Million SEK | 63.805% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | 87.252% |
| Biosergen AB | 5.08 Million SEK | 66.588% |
| Nanologica AB (publ) | 79.32 Million SEK | 97.858% |
| SynAct Pharma AB | 51.83 Million SEK | 96.722% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | 78.626% |
| BioInvent International AB (publ) | 90.45 Million SEK | 98.122% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | 67.295% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 99.064% |
| Pila Pharma AB (publ) | 1.79 Million SEK | 5.295% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | 86.668% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | 76.598% |